Opinion: A truce in the stem cell wars?
By Richard Hayes,
San Francisco Examiner
| 11. 24. 2006
The contentious midterm elections clearly left a mark on the politics of stem cell research, but it’s not clear what the mark signifies. Missouri’s closely watched stem cell initiative barely squeaked by with 51 per cent of the vote, despite a $30 million campaign financed almost entirely by a single wealthy couple. And in nine congressional races identified as high priority by stem cell research advocates, the stem cell candidate won in only four.
At the same time, at least 60 percent of all races in which stem cell research was an issue — including high-profile races for Congress, the Senate, and governorships — were won by the candidate supporting the research. And there’s no denying the frenzied TV and YouTube campaigning by partisans on all sides reinforced the identity of "stem cells" as an iconic trope of the culture wars.
Incoming Democratic House Speaker Nancy Pelosi has pledged a vote on federal stem cell funding "within the first 100 hours" of the new Congress. It appears there are now enough votes in the Senate to override a presidential veto...
Related Articles
By Grace Won, KQED [with CGS' Katie Hasson] | 12.02.2025
In the U.S., it’s illegal to edit genes in human embryos with the intention of creating a genetically engineered baby. But according to the Wall Street Journal, Bay Area startups are focused on just that. It wouldn’t be the first...
By Emma Cieslik, Ms. Magazine | 11.20.2025
Several recent Biopolitical Times posts (1, 2, 3, 4) have called attention to the alarmingly rapid commercialization of “designer baby” technologies: polygenic embryo screening (especially its use to purportedly screen for traits like intelligence), in vitro gametogenesis (lab-made eggs and sperm), and heritable genome editing (also termed embryo editing or reproductive gene editing). Those three, together with artificial wombs, have been dubbed the “Gattaca stack” by Brian Armstrong, CEO of the cryptocurrency company...
By Emily Glazer, Katherine Long, Amy Dockser Marcus, The Wall Street Journal | 11.08.2025
For months, a small company in San Francisco has been pursuing a secretive project: the birth of a genetically engineered baby.
Backed by OpenAI chief executive Sam Altman and his husband, along with Coinbase co-founder and CEO Brian Armstrong, the startup—called...